Results 11 to 20 of about 460,462 (263)
The bZIP Proteins of Oncogenic Viruses [PDF]
Viruses, 2020 Basic leucine zipper (bZIP) transcription factors (TFs) govern diverse cellular processes and cell fate decisions. The hallmark of the leucine zipper domain is the heptad repeat, with leucine residues at every seventh position in the domain. These leucine residues enable homo- and heterodimerization between ZIP domain α-helices, generating coiled-coil ...
Madeleine L. Stolz, Craig McCormick
openaire +3 more sources
Oncogenic Signaling Adaptor Proteins [PDF]
Journal of Genetics and Genomics, 2015 Signal transduction pathways activated by receptor tyrosine kinases (RTK) play a critical role in many aspects of cell function. Adaptor proteins serve an important scaffolding function that facilitates key signaling transduction events downstream of RTKs.
Leo Y, Luo, William C, Hahn
openaire +2 more sources
Identification of an oncogenic RAB protein [PDF]
Science, 2015 Cancer as a case of uncontrolled traffic Healthy cells are like skilled air traffic controllers. They continually move proteins to and from the cellular destinations where they are needed, usually without mishap, through an elaborate system of endomembranes.
Wheeler, D. B. +4 more
openaire +4 more sources
Oncogenic Potential of the Dual-Function Protein MEX3A [PDF]
Biology, 2021 MEX3A belongs to the MEX3 (Muscle EXcess) protein family consisting of four members (MEX3A-D) in humans. Characteristic for MEX3 proteins is their domain structure with 2 HNRNPK homology (KH) domains mediating RNA binding and a C-terminal really interesting new gene (RING) domain that harbors E3 ligase function.
Marcell Lederer +6 more
openaire +4 more sources
Targeting DUBs to degrade oncogenic proteins [PDF]
British Journal of Cancer, 2020 Targeted protein degradation has emerged as a strategy in cancer therapy. Yang et al. discovered that HBX19818, an inhibitor of the deubiquitinase (DUB) USP10, leads to the dual degradation of spleen tyrosine kinase (SYK) and FLT3, resulting in death of AML cells.
Cremer, Anjali, Stegmaier, Kimberly
openaire +2 more sources
Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML
Nature Communications, 2020 The oncogene MLL is frequently translocated in leukemia, resulting in oncogenic fusion proteins. Here, the authors report a temporally controlled mouse model of MLL-ENL driven leukemia AND identify therapeutic targets associated with early MLL-ENL driven
Silvia Basilico +13 more
doaj +1 more source
Oncogenic Properties of the EBV ZEBRA Protein [PDF]
Cancers, 2020 Epstein Barr Virus (EBV) is one of the most common human herpesviruses. After primary infection, it can persist in the host throughout their lifetime in a latent form, from which it can reactivate following specific stimuli. EBV reactivation is triggered by transcriptional transactivator proteins ZEBRA (also known as Z, EB-1, Zta or BZLF1) and RTA ...
Diego Germini +6 more
openaire +2 more sources
VAV Proteins as Double Agents in Cancer: Oncogenes with Tumor Suppressor Roles
Biology, 2021 Guanosine nucleotide exchange factors (GEFs) are responsible for catalyzing the transition of small GTPases from the inactive (GDP-bound) to the active (GTP-bound) states. RHO GEFs, including VAV proteins, play essential signaling roles in a wide variety
Myriam Cuadrado, Javier Robles-Valero
doaj +1 more source
Id Proteins - Tumor Markers or Oncogenes? [PDF]
Cancer Biology & Therapy, 2002 The Id (Inhibitor of differentiation or Inhibitor of DNA-binding) proteins act as dominant negative inhibitors of differentiation-specific basic Helix-Loop-Helix (bHLH) transcription factors. Id proteins negatively regulate cellular differentiation and they induce proliferation by modulating different cell cycle regulators both by direct and indirect ...
Jens, Hasskarl, Karl, Münger
openaire +2 more sources
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Nature Communications, 2022 Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering of T
Andrew Poole +24 more
doaj +1 more source